The Abigail Alliance is a 501(c)(3) non-profit that creates wider access to developmental cancer drugs and other experimental treatments for people with life-threatening illnesses.

Monday, February 25, 2019

Support the Research Subject Bill of Rights

The new federal Right to Try law provides important protections to physicians and drug companies that help terminally-ill patients access investigational medications outside of clinical trials, but the rights of research subjects under the act are ambiguous. The Research Subject Bill of Rights is a set of state laws that clarify the rights of terminally-ill patients who are seeking access to treatments being studied in clinical trials.

Friday, August 19, 2011

Press Release – August 19, 2011

Although the FDA approved the Melanoma drug PLX 4032 (Zelboraf) on Wednesday (August 17, 2011), what is not in the news is that the FDA is responsible for lives lost by not allowing access two years or more ago to this drug for people who were fighting for their lives and could not get into clinical trials for this efficacious drug.  This is nothing less than another clear avoidable FDA tragedy.

Thursday, March 3, 2011

From the Wall Street Journal – “The FDA and Slower Cures”

Last week, the Wall Street Journal published an article on the FDA which our President Frank Burroughs felt inclined to comment on.  View the full article here “The FDA and Slower Cures” and read Frank’s reaction below.

Thursday, December 23, 2010

Press Release – Expanded Access Program

The Abigail Alliance for Better Access to Developmental Drugs is happy to announce that there is now an expanded access program for the efficacious developmental metastatic melanoma drug PLX4032 (also known as RG7204 and RO5185426).   Information regarding the program can be found on at: , or by going to and searching for RO5185426.